Autopsy report · NCT05915897

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

“Unable to recruit subjects due to disease rarity”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Sanguine Biosciences

Sponsor type

Industry

Conditions

Chronic Granulomatous Disease

Interventions

Specimen Donation

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)
  “Unable to recruit additional subjects due to disease rarity” (96% match in meaning)
• Paresthesia Free Spinal Cord Stimulation (PF-SCS)
  “Unable to recruit subjects due to Covid pandemic” (77% match in meaning)
• The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
  “Inability to recruit eligible subjects” (75% match in meaning)
• Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery
  “Unable to recruit a sufficient number of subjects.” (75% match in meaning)
• FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
  “inability to recruit subjects” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.